THENAR MOTOR UNIT NUMBER ESTIMATES USING THE MULTIPLE POINT STIMULATION TECHNIQUE - REPRODUCIBILITY STUDIES IN ALS PATIENTS AND NORMAL SUBJECTS
THENAR MOTOR UNIT NUMBER ESTIMATES USING THE MULTIPLE POINT STIMULATION TECHNIQUE - REPRODUCIBILITY STUDIES IN ALS PATIENTS AND NORMAL SUBJECTS
复制标题
DOI：
10.1002/mus.880181211
复制
发表时间：
1995-12-01
期刊：
影响因子：
3.4
通讯作者：
FELICE, KJ
中科院分区：
文献类型：
--
作者：
FELICE, KJ
使用多点刺激 (MPS) 技术对 20 名肌萎缩侧索硬化症 (ALS) 患者和 16 名正常受试者进行鱼际运动单位数估计 (MUNE) 再现性的评估，MUNE 的计算方法是将鱼际复合肌肉动作电位负峰 (n-p) 面积除以 10 个最低阈值、全有或全无、表面记录的运动单位动作电位的平均 n-p 面积，进行了两项试验（重测）同一检查者在不同日期或同一天放置新电极，ALS 患者的平均测试 MUNE 为 43.4（SD：35.9，范围：6-145），正常受试者为 219.4（SD：80.8，范围：122-368），重测 MUNE 差异对于 ALS 患者或正常受试者不显着，重测相关系数 (r) 为ALS 患者为 0.99，正常受试者为 0.85。ALS 患者的重测值平均差异为 10%，正常受试者为 17%。使用 MPS 技术对鱼际 MUNE 进行重测的重现性在 ALS 患者和正常受试者中均较高。 MPS 技术在估计运动单位数量方面的可靠性可能使其成为跟踪进行性下运动神经元疾病患者（尤其是参加实验性药物试验的患者）病程的有用结果测量方法。 (C) 1995 约翰威利父子公司
Thenar motor unit number estimate (MUNE) reproducibility was assessed in 20 patients with amyotrophic lateral sclerosis (ALS) and 16 normal subjects using the multiple point stimulation (MPS) technique, The MUNE was calculated by dividing the thenar compound muscle action potential negative-peak (n-p) area by the mean n-p area of 10 lowest threshold, all-or-nothing, surface-recorded motor unit action potentials, Two trials (test-retest) were performed by the same examiner either on separate days or on the same day with new electrode placements, The mean test MUNE was 43.4 (SD: 35.9, range: 6-145) for ALS patients and 219.4 (SD: 80.8, range: 122-368) for normal subjects, Test-retest MUNE differences were not significant for ALS patients or normal subjects, The test-retest correlation coefficient (r) was 0.99 for ALS patients and 0.85 for normal subjects, The mean difference between test-retest values was 10% for ALS patients and 17% for normal subjects. Test-retest reproducibility of the thenar MUNE using the MPS technique is high in both ALS patients and normal subjects. The reliability of the MPS technique in estimating motor unit numbers may make it a useful outcome measure in following the course of patients with progressive lower motor neuron disease, especially those enrolled in experimental drug trials. (C) 1995 John Wiley & Sons, Inc.